UMA SALA DE LEITURA · TB-500 · SEGURANÇA E RECUPERAÇÃO
TB-500 and the safety questions the research has — and has not — answered
A peer-reviewed digest of the Thymosin Beta-4 fragment literature: preclinical tissue repair findings, the unresolved angiogenesis-and-cancer question, WADA prohibition, and the complete absence of published human injectable safety data.
What TB-500 is, and what the preclinical record shows
TB-500 is a synthetic heptapeptide — seven amino acids, sequence Ac-LKKTETQ — corresponding to positions 17 through 23 of Thymosin Beta-4 (Tβ4), the primary G-actin-sequestering protein in mammalian cells [1]. The compound weighs 796.9 daltons and is N-terminally acetylated, which confers some resistance to proteolytic degradation.
The preclinical record is substantial. Tβ4 and its active fragment have been studied in full-thickness wound models, transected ligament models, myocardial infarction models, traumatic brain injury protocols, and skeletal muscle injury preparations — across at least four species, in more than two dozen peer-reviewed papers [21].
The short summary: in animal models, the compound accelerates tissue repair, promotes new blood vessel formation, reduces inflammatory markers, and supports cell survival in ischemic conditions. The longer summary — the one that matters for anyone trying to understand whether TB-500 is safe — is that no published Phase I pharmacokinetic or safety trial for injectable TB-500 (Ac-LKKTETQ) in humans exists. Every injected human use of this compound occurs outside a regulated clinical framework [20].
This site holds both of those facts at the same time. The evidence is reviewed honestly: the findings where they are strong, the gaps where they are real, and the TB-500 side effects and risks the literature has documented — including theoretical concerns that the research has raised and not resolved.
Thymosin Beta-4 and TB-500: The Relationship Explained
Thymosin Beta-4 (Tβ4) is a 43-amino-acid endogenous protein expressed throughout mammalian tissues. Its primary function is G-actin sequestration — binding free actin monomers to regulate the pool available for directed cell movement during wound healing, immune response, and tissue remodeling.
TB-500 is only the central 7-amino-acid fragment of Tβ4. The LKKTETQ sequence at positions 17–23 contains the actin-binding domain responsible for Tβ4's wound-healing and matrix metalloproteinase induction activity. In vitro work confirmed that this minimal fragment recapitulates the full protein's MMP induction [1]. A separate wound healing study in db/db diabetic mice and aged mice found that the synthetic LKKTETQ peptide produced keratinocyte migration, wound contracture, and collagen deposition comparable to the full-length 43-amino-acid protein [2].
This distinction matters for reading the safety literature. Most mechanistic and clinical data covers the full Tβ4 protein. The only published Phase I human trial — 54 healthy Chinese volunteers, no serious adverse events, half-life 0.5–2.08 hours — used intravenous full-length recombinant Tβ4, not the TB-500 fragment [16]. A Phase II dry-eye trial using 0.1% topical Tβ4 ophthalmic solution found a favorable safety profile, with only 5.6% of treated subjects experiencing any treatment-emergent event versus 13.9% on placebo [23]. Both datasets cover the parent protein; neither applies directly to injected TB-500.
For research and clinical studies on what Tβ4 and TB-500 have been shown to do in animal models, the tissue-repair findings are covered in detail on the research page. The safety data, regulatory status, and open questions are documented on the TB-500 side effects page.
What is TB-500? The three findings the literature consistently shows
Across the preclinical record, three findings recur with enough consistency to treat as the compound's working profile in animal models.
Tissue repair acceleration. In rat full-thickness wound models, Tβ4 administration increased reepithelialization by 42% at day 4 and up to 61% at day 7 compared to saline controls — with 2–3-fold stimulated keratinocyte migration in cell assays [3]. In a surgically transected rat medial collateral ligament model, local delivery of 1 µg Tβ4 in fibrin sealant produced superior biomechanical properties and improved collagen fiber organization at four weeks [9]. In mouse melanoma, dystrophic mouse, and skeletal muscle injury models, the compound accelerated myoblast wound closure and recruited satellite cells to injury sites [10][11].
Angiogenesis and cardiovascular activity. At 5.37 mg/kg intraperitoneal in Sprague-Dawley rats following permanent coronary artery occlusion, Tβ4 reduced infarct size by 43% at 28 days and preserved hemodynamic function [6]. In traumatic brain injury models (Wistar rats, 6–30 mg/kg IP), 30 mg/kg produced significantly improved sensorimotor recovery, reduced cortical lesion volume, and enhanced hippocampal neurogenesis [7].
Immune modulation. At 12 mg/kg/day intraperitoneal for 4 weeks in NAFLD mice, Tβ4 shifted macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, reducing TNF-alpha and IL-1beta while increasing ARG1 and IL-10 [22].
These findings are all preclinical. The frequently asked questions page addresses what they do and do not tell us about human use.
The open questions this site does not hide
TB-500 promotes angiogenesis via VEGF upregulation — the same vascularization pathway exploited by tumors. In mouse melanoma models, Tβ4 overexpression produced 4.3 times more lung metastases and 4.4-fold greater tumor blood vessel formation compared to controls [12]. In human colon cancer tissue and mouse tumor cell lines, Tβ4 was found to stabilize HIF-1alpha protein, directly inducing VEGF expression [13]. In human pancreatic cancer cell lines, Tβ4 was overexpressed 3.7–4.5-fold versus normal ductal epithelium, and activated JNK pathways promoting cancer cell survival [14].
No human study has confirmed that exogenous TB-500 causes cancer. No study rules it out. Researchers formally flag the TB-500 cancer risk as an unresolved question.
Beyond the cancer question: the FDA designated TB-500 a Category 2 bulk drug substance (safety concerns; not permitted for pharmaceutical compounding for humans) between October 2023 and February 2024. WADA prohibits TB-500 and Thymosin Beta-4 in competitive sport under the growth factors and growth factor modulators category — in- and out-of-competition. A Canadian athlete received a 4-year ineligibility for a non-analytical positive involving TB-500 [18].
A 2023 analytical study found that internet-marketed TB500/TB1000 products are inconsistent in composition relative to their label descriptions — indicating misbranding or adulteration risks independent of the compound's own pharmacology [17].
All of these are documented here. The welcome on this site is the honesty.